APRI vs. BNTC, AGE, TNXP, MNPR, ABVC, IMNN, MIRA, ERNA, RDHL, and NNVC
Should you be buying Apricus Biosciences stock or one of its competitors? The main competitors of Apricus Biosciences include Benitec Biopharma (BNTC), AgeX Therapeutics (AGE), Tonix Pharmaceuticals (TNXP), Monopar Therapeutics (MNPR), ABVC BioPharma (ABVC), Imunon (IMNN), MIRA Pharmaceuticals (MIRA), Eterna Therapeutics (ERNA), RedHill Biopharma (RDHL), and NanoViricides (NNVC). These companies are all part of the "medical" sector.
Apricus Biosciences (NASDAQ:APRI) and Benitec Biopharma (NASDAQ:BNTC) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, valuation, community ranking, risk, earnings, media sentiment, institutional ownership and dividends.
In the previous week, Benitec Biopharma had 3 more articles in the media than Apricus Biosciences. MarketBeat recorded 3 mentions for Benitec Biopharma and 0 mentions for Apricus Biosciences. Apricus Biosciences' average media sentiment score of 0.00 equaled Benitec Biopharma'saverage media sentiment score.
Apricus Biosciences has a beta of 1.2, meaning that its share price is 20% more volatile than the S&P 500. Comparatively, Benitec Biopharma has a beta of 1.03, meaning that its share price is 3% more volatile than the S&P 500.
Apricus Biosciences has higher revenue and earnings than Benitec Biopharma.
19.9% of Apricus Biosciences shares are owned by institutional investors. Comparatively, 52.2% of Benitec Biopharma shares are owned by institutional investors. 2.3% of Apricus Biosciences shares are owned by company insiders. Comparatively, 4.3% of Benitec Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Apricus Biosciences received 49 more outperform votes than Benitec Biopharma when rated by MarketBeat users. Likewise, 69.91% of users gave Apricus Biosciences an outperform vote while only 63.73% of users gave Benitec Biopharma an outperform vote.
Benitec Biopharma has a consensus target price of $16.00, suggesting a potential upside of 131.88%. Given Benitec Biopharma's higher possible upside, analysts clearly believe Benitec Biopharma is more favorable than Apricus Biosciences.
Benitec Biopharma's return on equity of -204.34% beat Apricus Biosciences' return on equity.
Summary
Benitec Biopharma beats Apricus Biosciences on 8 of the 13 factors compared between the two stocks.
Get Apricus Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for APRI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding APRI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Apricus Biosciences Competitors List
Related Companies and Tools
